Detailed information for compound 1938727

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 299.414 | Formula: C17H25N5
  • H donors: 2 H acceptors: 2 LogP: 1.74 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: CNCCN(c1cncc(c1)CCc1cc(C)cc(n1)N)C
  • InChi: 1S/C17H25N5/c1-13-8-15(21-17(18)9-13)5-4-14-10-16(12-20-11-14)22(3)7-6-19-2/h8-12,19H,4-7H2,1-3H3,(H2,18,21)
  • InChiKey: BAILAIZRWKFZJT-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Rattus norvegicus Nitric-oxide synthase, brain Starlite/ChEMBL References
Bos taurus Nitric-oxide synthase, endothelial Starlite/ChEMBL References
Homo sapiens nitric oxide synthase 1 (neuronal) Starlite/ChEMBL References
Mus musculus nitric oxide synthase 2, inducible Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Plasmodium vivax NADPH-cytochrome p450 reductase, putative 0.0118 1 1
Trypanosoma brucei NADPH--cytochrome P450 reductase, putative 0.0118 1 0.5
Echinococcus granulosus NADPH cytochrome P450 reductase 0.0118 1 1
Toxoplasma gondii flavodoxin domain-containing protein 0.0059 0 0.5
Echinococcus multilocularis NADPH dependent diflavin oxidoreductase 1 0.0118 1 1
Trichomonas vaginalis sulfite reductase, putative 0.0118 1 1
Trypanosoma cruzi p450 reductase, putative 0.0118 1 0.5
Echinococcus granulosus NADPH dependent diflavin oxidoreductase 1 0.0118 1 1
Giardia lamblia Hypothetical protein 0.0105 0.7743 0.5
Echinococcus multilocularis NADPH cytochrome P450 reductase 0.0118 1 1
Chlamydia trachomatis sulfite reductase 0.0073 0.2407 0.5
Loa Loa (eye worm) FAD binding domain-containing protein 0.0118 1 1
Schistosoma mansoni 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase 0.0073 0.2407 0.2407
Trypanosoma cruzi NADPH-dependent FMN/FAD containing oxidoreductase, putative 0.0118 1 0.5
Brugia malayi FAD binding domain containing protein 0.0118 1 1
Trypanosoma cruzi cytochrome P450 reductase, putative 0.0118 1 0.5
Schistosoma mansoni NADPH flavin oxidoreductase 0.006 0.0151 0.0151
Giardia lamblia Nitric oxide synthase, inducible 0.0105 0.7743 0.5
Toxoplasma gondii flavodoxin domain-containing protein 0.0059 0 0.5
Plasmodium falciparum nitric oxide synthase, putative 0.0118 1 0.5
Leishmania major NADPH-cytochrome p450 reductase-like protein 0.0118 1 1
Leishmania major p450 reductase, putative 0.0118 1 1
Schistosoma mansoni cytochrome P450 reductase 0.0118 1 1
Mycobacterium ulcerans formate dehydrogenase H FdhF 0.0118 1 0.5
Loa Loa (eye worm) hypothetical protein 0.0118 1 1
Trypanosoma cruzi cytochrome P450 reductase, putative 0.0118 1 0.5
Trypanosoma brucei NADPH--cytochrome P450 reductase, putative 0.0118 1 0.5
Trypanosoma brucei NADPH-dependent diflavin oxidoreductase 1 0.0118 1 0.5
Trypanosoma brucei NADPH-cytochrome p450 reductase, putative 0.0118 1 0.5

Activities

Activity type Activity value Assay description Source Reference
Ki (binding) = 17 nM Inhibition of rat recombinant nNOS expressed in Escherichia coli by oxyhemoglobin NO assay ChEMBL. 26120733
Ki (binding) = 59 nM Inhibition of human recombinant nNOS expressed in Escherichia coli by oxyhemoglobin NO assay ChEMBL. 26120733
Ki (binding) = 2152 nM Inhibition of mouse recombinant iNOS expressed in Escherichia coli by oxyhemoglobin NO assay ChEMBL. 26120733
Ki (binding) = 12910 nM Inhibition of bovine recombinant eNOS expressed in Escherichia coli by oxyhemoglobin NO assay ChEMBL. 26120733

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.